Rucaparib
Rucaparib
Rucaparib (pronounced roo-KAP-a-rib) is a pharmaceutical drug used in the treatment of certain types of cancer, specifically ovarian cancer and prostate cancer. It is a type of PARP inhibitor, which works by preventing cancer cells from repairing their own DNA, leading to cell death.
Etymology
The name "Rucaparib" is derived from the chemical structure of the drug, which is a member of the class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. The "ru" comes from the first two letters of "rubidium", a chemical element used in the synthesis of the drug, and "caparib" is a common suffix used for drugs in this class.
Usage
Rucaparib is used in the treatment of advanced ovarian cancer that has been treated with two or more chemotherapies and continues to progress. It is also used in the treatment of metastatic castration-resistant prostate cancer with a specific genetic mutation.
Related Terms
- Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells.
- Ovarian Cancer: A type of cancer that begins in the ovaries.
- Prostate Cancer: A type of cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm.
- PARP inhibitor: A type of drug that blocks an enzyme called poly (ADP-ribose) polymerase (PARP). PARP helps repair DNA when it becomes damaged.
Side Effects
Common side effects of Rucaparib include fatigue, nausea, vomiting, anemia, abdominal pain, and increased liver enzymes. More serious side effects can include myelodysplastic syndrome, acute myeloid leukemia, and pneumonitis.
External links
- Medical encyclopedia article on Rucaparib
- Wikipedia's article - Rucaparib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski